- Huntington's Disease Insights
- Posts
- Huntington's Disease Insights
Huntington's Disease Insights
This week's must-know community updates, latest research & events
New This WeekExciting news! There is now a new section featuring clinical trials that are actively recruiting patients. This highly requested addition gives you direct access to cutting-edge research opportunities that could shape the future of treatment. Stay informed about potentially life-changing studies and let us know what you think by replying to this email! | ||||||||||||||||
Top StoriesThe Fight for Progress: Women Leading the Charge in Rare Disease Advocacy At South By South West 2025, a panel of female leaders tackled the systemic barriers in rare disease research, highlighting the challenges of delayed diagnoses and funding gaps. They explored how AI-driven diagnostics, patient advocacy, and drug repurposing are accelerating progress in a field long overlooked. Read More →HDSA Smash HD Combines Pickleball and Charity Pickleball enthusiasts gather for a charity event to support those affected by Huntington's Disease, combining sports with fundraising efforts. Read More → | ||||||||||||||||
Latest ResearchIn the quest for treatments for Huntington's Disease (HD), Feigin et al. (2025) have identified a potential therapeutic target in neuroinflammation, specifically astrogliosis, which is a harmful process where support cells in the brain become overactive. They suggest that Pepinemab, an antibody that blocks semaphorin 4D (SEMA4D), could be effective in modulating this detrimental inflammation and its associated effects. SEMA4D is implicated in the progression of neurodegenerative diseases, and by inhibiting it, Pepinemab may offer a new avenue for disease-modifying therapy in HD. The significance of this research lies in the innovative approach to slowing down or altering the course of HD by targeting a specific aspect of neuroinflammation. While the study does not provide specific data on clinical outcomes, the identification of SEMA4D as a therapeutic target and the development of Pepinemab as a blocking agent represent important steps forward in the search for effective treatments for HD and possibly other neurodegenerative diseases. | ||||||||||||||||
Clinical Trials This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
NYSCF Scientific Discovery Biobank
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
| ||||||||||||||||
Click Here to Join Our CommunityJoin Our Waitlist | ||||||||||||||||